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Abstract: Low-dose aspirin is widely used in the primary and secondary prevention of 
  cardiovascular events, but is associated with a range of upper gastrointestinal side effects. In 
this review, we summarize the rationale for low-dose aspirin therapy, quantify the risk for upper 
gastrointestinal side effects, identify the risk factors involved, and provide an overview of preven-
tive strategies, thereby focusing on the rationale and clinical utility of combining proton-pump 
inhibitors with low-dose aspirin.
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Introduction
The use of aspirin-like compounds predates the dawn of modern medicine. The earliest 
known references to the medicinal use of myrtle and willow tree bark, original sources 
of salacin (named after its source Salix alba, the White Willow) can be traced back to 
the ancient Egyptians. The application of willow tree bark for stiff and painful joints 
is recommended in Ebers Papyrus, a medical text dated to the reign of Amenhotep I, 
around 1534 BC. Hippocrates of Cos (460-377 BC) who spent several years in Egypt 
studying medicine, also noted that chewing the bitter leaves of the willow tree reduced 
pain.1–4 In 1899 Felix Hoffmann, a chemist working for the Bayer company, perfected 
the formula for acetylating salicylic acid to make it less bitter and less gastrotoxic. 
Acetylsalicylic acid, the world’s first truly synthetic and eventually most successful 
drug, was patented on March 6, 1899 and was called “Aspirin” (A- from Acetyl, -spir- 
from Spiraea ulmaria [meadowsweet, which also contains salacin] and -in as a then 
typical name-ending for medicines).5,6
Nowadays, aspirin is most widely known for its application in strategies to reduce 
cardiovascular risk, due to its anticoagulant properties first discovered by Lawrence L 
Craven, a general practitioner from Glendale, California, in the 1940s, who observed 
increased bleeding in children who chewed aspirin gum after tonsillectomy. He started 
prescribing an aspirin a day to overweight middle-aged men with sedentary lifestyles 
and to patients who had recovered from previous heart attacks. After having treated 
nearly 8000 patients and noting not a single myocardial infarction or stroke among them, 
Craven published his results, recommending aspirin as “a safe and effective method 
of preventing coronary thrombosis”.7 However, it took more than another 30 years 
and the publication of the first systematic data showing aspirin use to be   associated 
with a reduction in myocardial infarction and stroke, by Elwood in 1974, before the Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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US Food and Drug Administration would endorse the rec-
ommendation to prescribe aspirin to individuals at high risk 
for cardiovascular events.1,8,9 Since then, many studies have 
been published on cardiovascular risk reduction strategies 
based on the use of aspirin in various patient groups. One 
should distinguish both primary and secondary prevention 
strategies, and low- and high-risk patient groups, ie, healthy 
individuals and patients with unfavorable cardiovascular risk 
profiles, asymptomatic vascular disease, or diabetes. Finally, 
the benefits of aspirin may be negatively influenced by a 
feature known as “aspirin resistance” as demonstrated by a 
lack of response on platelet function testing, and by aspirin’s 
potential for gastrotoxicity.
This article provides an overview for the practicing 
physician of the literature regarding the effects of aspirin 
and nonsteroidal anti-inflammatory drugs (NSAIDs) on the 
gastrointestinal mucosa and the rationale and practice of 
various strategies to counteract these side effects.
Methods
We searched Medline for English language articles published 
up to 2010, using the keywords: acetylsalicylic acid, aspirin, 
cardiovascular, NSAIDs, adverse effects, gastrointestinal, 
and proton-pump inhibitors. Abstracts were screened for 
relevance, and publications relating to aspirin, gastrointestinal 
side effects, and proton pump inhibitors were obtained. Addi-
tional references were identified from the bibliographies of 
the retrieved reports and from review articles. Further sources 
of information were retrieved from the Internet.
Aspirin and cardiovascular  
risk reduction
The most robust data on the value of aspirin to prevent 
  cardiovascular events are on secondary prevention in 
patients with occlusive cardiovascular disease (Table 1). In 
2002, the   Antithrombotic Trialists’ Collaboration published 
a   meta-analysis of 287 randomized trials of an antiplatelet 
regimen versus control or versus another antiplatelet regimen 
in high-risk patients.10 Sixty-five trials were on aspirin alone 
and 48 on a combination containing aspirin. The prescription 
of any antiplatelet therapy reduced the combined outcome 
of any serious vascular event by about one quarter, nonfatal 
myocardial infarction by one third, nonfatal stroke by one 
quarter, and vascular mortality by one sixth. Absolute risk 
reductions mainly varied by patients’ absolute risk, being 
36 per 1000 treated for two years in patients with previous 
myocardial infarction or stroke and 22 per 1000 treated for 
other high-risk patients. The results for aspirin were similar 
to that of all antiplatelet therapies taken together.   High-dose 
aspirin (500–1500 mg daily) was no more effective than 
  medium-dose (160–325 mg) or low-dose (75–150 mg) 
  aspirin.10 In the context of acute ischemic stroke, aspi-
rin treatment is associated with a definite benefit during 
  hospitalization and in posthospital prognosis. A combined 
analysis of the pooled data of two major trials on this subject, 
comprising data for 40,000 patients, showed a reduction of 
9 per 1000 (2P = 0.001) in the overall risk for further stroke 
or death in hospital.11
The most recent meta-analysis from the previously men-
tioned Antithrombotic Trialists’ Collaboration analyzed the 
available individual participant data for both secondary and 
primary cardiovascular prevention using aspirin.12 Results 
from primary and secondary prevention data were similar 
for men and women regarding the proportional reductions 
in the aggregate of all serious vascular events. The study 
confirmed previous conclusions regarding secondary pre-
vention by showing a statistically and clinically significant 
reduction in serious vascular events (6.7% with aspirin 
versus 8.2% with placebo per year), with similar results in 
both men and women. However, results for primary preven-
tion are disappointing. Six randomized, controlled, primary 
prevention trials were included, covering 95,000 individuals 
at low average risk with 660,000 person-years of follow-up. 
Aspirin allocation yielded a 12% proportional reduction in 
serious vascular events (0.51% with aspirin versus 0.57% 
in controls per year, P = 0.0001), mainly due to a reduction 
in nonfatal myocardial infarction (0.18% versus 0.23% per 
year, P , 0.0001). The incidence of stroke and vascular mor-
tality did not differ significantly. In the view of an increase in 
major gastrointestinal and other extracranial bleeding (0.10% 
versus 0.07% per year, P , 0.0001), the net benefit of aspirin 
in the primary prevention of cardiovascular events remains 
subject to discussion.12
In search of intermediate patient groups that might indeed 
take advantage of treatment with aspirin to reduce the occur-
rence of future occlusive vascular disease, studies were done 
in patients with diabetes mellitus and asymptomatic vascular 
disease. A meta-analysis on seven prospective, randomized, 
controlled trials including 11,618 diabetes mellitus patients, 
with follow-up of 3.7–10.1 years, showed that aspirin therapy 
was not associated with a significant reduction in major 
cardiovascular events (11.1% with aspirin versus 12.1% in 
controls, relative risk [RR], 0.92; 95% confidence intervals 
[CI]: 0.83–1.02) or deaths (6.4% with aspirin versus 7.0% in 
controls, RR, 0.95; 95% CI: 0.71–1.27).13 Even though aspi-
rin did not significantly increase the risk of major bleeding Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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Table 1 Aspirin in the primary and secondary prevention of cardiovascular disease
Study Population Methods Results Conclusion
Chen et al11 Acute ischemic  
stroke (n = 40,000)
Meta-analysis of  
two RCTs
9/1000 (8.2%  
aspirin versus 9.1%  
control, 2P = 0.001) proportional 
reduction in recurrent stroke  
or inhospital death
early aspirin is of  
benefit in patients with 
suspected acute ischemic 
stroke
Antithrombotic  
Trialists’  
Collaboration12
Primary (n = 95,000,  
660,000 py) and  
secondary prevention 
(n = 17,000, 43,000 py)  
of serious vascular events 
(myocardial infarction,  
stroke, vascular death)
Meta-analysis of  
six primary prevention  
and 16 secondary  
prevention trials
Risk reduction primary 
prevention 12%  
(0.51% aspirin versus  
0.57% control, P = 0.0001) 
Major bleeding 0.10%  
aspirin versus 0.07%  
control, P , 0.0001) 
Risk reduction  
secondary prevention  
18% (6.7% aspirin versus  
8.2% control, P , 0.0001)
Aspirin is of benefit in 
secondary prevention  
of serious vascular events;  
the net benefit, considering 
risk of major bleeding, 
in primary prevention  
is uncertain
Zhang et al13 Primary prevention of 
cardiovascular events  
in patients with  
diabetes (n = 11,618)
Meta-analysis of  
seven RCTs
No reduction in serious 
cardiovascular events  
(11.1% aspirin versus  
12.1% control, RR 0.92;  
95% Ci 0.83–1.02) or  
death (6.4% aspirin  
versus 7.0 control,  
RR 0.95; 95% Ci 0.71–1.27)
Aspirin does not reduce  
the risk of occlusive  
vascular disease or death 
in patients with diabetes 
mellitus at otherwise  
low risk for occlusive  
vascular disease
Fowkes et al15 Primary prevention of 
nonfatal coronary event, 
stoke or revascularization  
in patients with  
asymptomatic vascular 
disease, ie, patients with 
low ankle brachial  
index (n = 28,980)
Double-blind RCT  No reduction in vascular 
events (13.7/1000 py 
aspirin versus 13.3/1000  
py placebo, HR 1.03;  
95% Ci 0.84–1.27)
in patients with  
subclinical atherosclerotic 
vascular disease aspirin 
does not reduce the risk  
for occlusive vascular events
Berger et al17 Primary prevention  
in patients with  
peripheral artery  
disease (n = 5269)
Meta-analysis  
of 18 RCTs
No reduction in nonfatal 
myocardial infarction,  
nonfatal stroke (8.9%  
aspirin versus 11.0 control, 
RR 0.88; 95% Ci 0.76–1.04),  
or cardiovascular death  
(8.0% aspirin versus  
8.8 control, RR 0.98;  
95% Ci 0.83–1.17)
No significant benefit  
of aspirin on the occurrence 
of serious cardiovascular 
events in patients with 
peripheral artery disease
Abbreviations: CI, confidence interval; RR, relative risk; RCT, randomized controlled trial; py, patient years.
(3.0% with aspirin versus 1.7% in controls, RR, 2.46; 95% 
CI: 0.70–8.61), based on these data aspirin has no place in 
the routine management of patients with diabetes mellitus 
at otherwise low risk for occlusive vascular disease. This 
recommendation was recently endorsed jointly by the Ameri-
can Diabetes Association, American Heart Association, and 
American College of Cardiology.13,14
There is no meta-analysis available on prescription of 
aspirin to patients with asymptomatic vascular disease. 
However, a recent double-blind, randomized, controlled trial 
showed no benefit of aspirin versus placebo after a mean 
follow-up of 8.2 years in reducing the primary endpoint of 
fatal or nonfatal coronary events, strokes, or revasculariza-
tions in otherwise healthy individuals with asymptomatic 
occlusive vascular disease as suspected by a low ankle 
brachial index on screening (13.7 per 1000 person-years 
with aspirin versus 13.3 per 1000 person-years with pla-
cebo, hazard ratio [HR], 1.03; 95% CI: 0.84–1.27).15 Even 
though the study was underpowered to detect a smaller 
than 25% difference in the primary study outcome, and 
one might raise questions on the ankle brachial index to 
diagnose subclinical vascular disease, these data do not 
indicate a clinically relevant advantage of long-term aspi-
rin use in these individuals.16 Furthermore, the findings Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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in this trial are supported by findings in a meta-analysis 
on aspirin for the prevention of cardiovascular events in 
patients with overt peripheral artery disease, that could only 
demonstrate a reduction in nonfatal stroke, but not in all 
primary cardiovascular endpoints. This meta-analysis on 18 
randomized controlled trials involving 5269 patients, found 
similar rates in aspirin-treated patients versus controls for 
cardiovascular events (8.9% with aspirin versus 11.0% in 
controls, RR, 0.88; 95% CI: 0.76–1.04) or any death (8.0% 
with aspirin versus 8.8% in controls, RR, 0.98; 95% CI: 
0.83–1.17).16,17
Besides underlying disease and absolute risk, whether 
the individual patient benefits from long-term aspirin use 
might also depend on the phenomenon of “aspirin resis-
tance”, ie, the observation that some patients require a 
higher dose of aspirin than is normally recommended to 
achieve the expected antiplatelet effect. The cause of this 
insufficient response has not yet been fully elucidated, 
and may be a composite of low dosage, incompliance, 
variations in absorbing capacities, and/or underlying 
genetic predispositions.18 The disappointing results of 
aspirin therapy in diabetes patients may in part be due to 
biochemical interactions leading to diminished effects of 
aspirin on platelet function in these patients.19 Regardless 
of the mechanisms involved, a meta-analysis on 20, mainly 
cohort, studies totaling 2930 patients with cardiovascular 
disease using aspirin in a dose of 75–325 mg daily, showed 
810 (28%) of the patients to be aspirin-resistant. Aspirin-
resistant patients were at a greater risk of death, acute 
coronary syndrome, failure of vascular intervention or a 
new cerebrovascular event; 39% of the aspirin-resistant 
patients experienced a cardiovascular event compared with 
16% of the aspirin-sensitive patients (odds ratio [OR], 3.85; 
95% CI: 3.08–4.80).18
Aspirin and upper gastrointestinal 
side effects
It is now estimated that 50 million Americans have started 
on aspirin for cardiovascular prevention.20 Aspirin use is 
associated with a wide variety of upper gastrointestinal side 
effects. These side effects range from dyspepsia to acute 
mucosal damage, erosions, ulcers, and ulcer complications, 
such as ulcer bleeding and death. There is increasing evi-
dence that a large proportion of hospitalizations for gastro-
intestinal bleeding is now attributable to low-dose aspirin 
use. In a recent nationwide observational study from Spain, 
low-dose aspirin was found to be responsible for 12% of 
all severe gastrointestinal events and associated deaths.21 
Mortality attributable to the use of NSAIDs or aspirin is 
estimated to be 20–25 cases per million people. One third 
of these are attributable to low-dose aspirin.21 The earliest 
report on aspirin-induced gastric damages, however, dates 
back nearly 75 years, when Douthwaite and Lintott used 
rigid endoscopy to report aspirin-induced gastric damage in 
a series of patients in 1938.22
Dyspepsia is common in aspirin and in nonaspirin NSAID 
users, being reported by 15%–40% of patients and causing 
10% to discontinue their NSAID treatment.23 However, 
there is a poor correlation between dyspeptic symptoms and 
mucosal damage, because approximately half of NSAID-
using patients with dyspeptic symptoms have normal mucosa 
upon endoscopy.24 In a prospective study of 187 patients 
taking low-dose aspirin as cardiovascular prophylaxis, 
20% of patients reported dyspeptic symptoms, again with a 
Table 2 Gastrointestinal bleeding risk associated with use of low-dose aspirin
Study Population Methods Results Conclusion
Derry and Loke20 Low-dose aspirin use  
as antiplatelet agent 
(n = 66,000)
Meta-analysis  
of 24 RCTs
1.05% absolute risk increase 
for gastrointestinal bleeding 
(2.47% aspirin versus 1.42% 
placebo, OR 1.68; 95%  
Ci 1.51–1.88)
Long-term therapy with aspirin  
is associated with a significant  
increase in the incidence  
of gastrointestinal hemorrhage
McQuaid and Laine33 Low-dose aspirin or 
clopidogrel use for 
cardiovascular prophylaxis 
(n = 57,000 on aspirin)
Meta-analysis  
of 14 RCTs
Absolute increase in major 
gastrointestinal bleeding 
episodes (1.7/1000 aspirin 
versus 0.97/1000 placebo,  
RR 2.07; 95% Ci 1.61–2.66)
Low-dose aspirin increases the  
risk of major bleeding by  
approximately 70%; the absolute  
increase in bleeding risk is small
Sorensen et al34 Low-dose aspirin in general 
population (n = 27,694)
Cohort study increase in rate of  
hospitalization for upper  
gastrointestinal bleeding  
(1.3/1000 aspirin versus  
0.6/1000 general population,  
RR 2.6; 95% Ci 2.2–2.9)
Use of low-dose aspirin is  
associated with an increased risk   
of upper gastrointestinal bleeding
Abbreviations: CI, confidence interval; RR, relative risk; RCTs, randomized controlled trials; OR, odds ratio.Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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poor correlation between dyspeptic symptoms and mucosal 
damage.25 The mechanisms by which aspirin and nonaspirin 
NSAIDs induce dyspepsia is not clear.
Although some topical gastroduodenal injury may 
occur through local irritant effects of aspirin on the gastric 
epithelium, postabsorptive systemic inhibition of gastroin-
testinal COX-1 and subsequent inhibition of prostaglandin 
synthesis probably plays a dominant role in the pathogenesis 
of aspirin-induced mucosal damage. Use of enteric-coated 
or buffered aspirin, designed to resist disintegration in the 
stomach and dissolving in the more alkaline environment of 
the duodenum, does not appear to decrease the risk of major 
upper gastrointestinal bleeding and neither does parenteral 
or transdermal COX inhibition.26 Furthermore, rates of pep-
tic ulcer development in patients taking low-dose aspirin 
are similar to those in patients taking effervescent calcium 
carbasalate, a more easily dissolvable form of aspirin, that 
reduces the possibility of increased localized aspirin con-
centrations. The damaging effects of aspirin and nonaspirin 
NSAIDs on the gastroduodenal mucosa are therefore thought 
to be mainly systemic, and enteric-coated preparations may 
not be assumed to be fully gastroprotective. By inhibition of 
gastrointestinal COX-1, aspirin may reduce mucosal blood 
flow causing local ischemic injury. This ischemia-reperfusion 
injury may occur very early after NSAID administration.
Aspirin may further impair specific prostaglandin-
dependent defenses which protect the gastric mucosa, such 
as the secretion of the thick bicarbonate-containing mucous 
layer lining the interior of the stomach, which buffers lumi-
nal gastric acid and thus protects the stomach wall. When 
these defenses have been weakened, a second wave of 
injury caused by luminal gastric acid may facilitate deeper 
ulceration and even perforation of the stomach wall.23 Due 
to the concurrent inhibition of blood platelet aggregation, 
aspirin-induced gastrointestinal ulcers may have an increased 
tendency to bleed. Inhibition of prostaglandin synthesis 
reduces epithelial cell turnover and repair, and mucosal 
immunocyte function.27
Neutrophils have been shown to play a role in NSAID 
gastropathy, and intracellular adhesion molecule 1 and tumor 
necrosis factor-alpha may mediate neutrophil adherence 
within the gastric microcirculation.28 NSAIDs can also inhibit 
the healing of pre-existing lesions by interfering with the pro-
cess of restitution, leading to the formation of hemorrhagic 
mucosal erosions. However, it has also been shown that the 
stomach may adapt to repeated exposure to aspirin and that 
long-term aspirin use increases the resistance of the stomach 
to damage by NSAIDs and other irritants.28,29
Mucosal damage may occur within minutes after exposure 
to aspirin, and may either heal or develop into ulcers.30 Superfi-
cial damage or erosions occur in approximately 50% of asymp-
tomatic patients on long-term treatment with low-dose aspirin.25 
In the previously mentioned study of 187 patients using low-
dose aspirin for cardiovascular protection, the point prevalence 
of endoscopic ulcers was 11% (95% CI: 6.3%–15.1%) and 
the three-month incidence was 7% (95% CI: 2.4%–11.8%).25 
However, the only placebo-controlled study of the occurrence 
of low-dose aspirin-associated endoscopic ulcers did not find 
significantly different incidence rates between enteric-coated 
aspirin 81 mg/day (7.3%) and placebo (5.8%) at three months.31 
However, the clinical significance of these findings is unclear, 
because the incidence of endoscopic ulcers is far greater than 
the incidence of more clinically relevant upper gastrointestinal 
complications, such as ulcer bleeding or perforation. Although 
endoscopic ulcers are often taken as the primary endpoint in 
clinical trials, the real target of prevention is gastrointestinal 
complications, which unlike endoscopic ulcers are associated 
with significant morbidity and mortality rates. The numbers 
needed to treat to prevent a gastrointestinal complication is usu-
ally much higher than the numbers needed to treat to prevent an 
endoscopic ulcer. The risk of aspirin-associated gastrointestinal 
complications can be assessed in the safety data from numer-
ous placebo-controlled trials primarily designed to evaluate 
the efficacy of low-dose aspirin in preventing cardiovascular 
events.10,20,32,33 One meta-analysis of 24 randomized controlled 
trials with almost 66,000 participants demonstrated a one per-
cent absolute risk increase for aspirin compared with placebo. 
Gastrointestinal bleeding occurred in 2.47% of patients taking 
aspirin compared with 1.42% of patients taking placebo, at an 
average of 28 months (OR, 1.68 [95% CI: 1.5–1.88] and number 
needed to harm 106 [95% CI: 82–140]).20 In a meta-analysis 
of 14 randomized placebo-controlled trials with over 57,000 
patients on low-dose aspirin (75–325 mg/day), the RR of major 
gastrointestinal bleeding that was fatal or required hospitaliza-
tion or transfusion was 2.07 with aspirin versus placebo (95% 
CI: 1.61–2.66). The pooled incidence of major gastrointestinal 
bleeding was 1.2 per 1000 patients per year (absolute annual 
increase in risk 0.12%; 95% CI: 0.07%–0.19%). Based on this 
value, 833 patients (95% CI: 526–1429 patients) would need 
to be treated with low-dose aspirin instead of placebo for one 
year to cause one major gastrointestinal bleeding episode (the 
number needed to harm was 833).33
The results from the randomized controlled trials are 
generally consistent with the results from observational 
  studies, where the OR of gastrointestinal bleeding has been 
in the range 1.3–3.2.28 In a five-year observational study from Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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Denmark, hospitalization for gastrointestinal bleeding was 
assessed in a cohort of 27,694 patients using low-dose aspirin, 
and compared with that in the general population.34 Rate of 
hospitalization for upper gastrointestinal bleeding in patients 
without aspirin, NSAIDs, anticoagulants, corticosteroids, or 
conditions predisposing to gastrointestinal bleeding was 0.6 
per 1000 patients per year. The absolute annual incidence 
of gastrointestinal bleeding in patients with aspirin was 1.3 
per 1000 patients per year (RR, 2.6; 95% CI: 2.2–2.9).34 The 
higher rates of gastrointestinal bleeding seen in observational 
studies than in randomized controlled trials may reflect the 
fact that patients who are at increased risk for gastrointestinal 
bleeding would generally have been excluded from participat-
ing in randomized controlled trials (Table 2).
Risk factors for NSAID-related 
gastrointestinal disease
Multiple studies have identified additional risk factors for the 
development of gastrointestinal ulcers during NSAID use. 
Risk factors include advanced age, a prior history of ulcers, 
high-dosage or multiple NSAIDs, concurrent use of corticos-
teroids, anticoagulants, aspirin, platelet inhibitors, or sero-
tonin reuptake inhibitors, infection with Helicobacter pylori 
and the presence of comorbid conditions, such as diabetes 
mellitus, heart failure, or rheumatoid arthritis.35 There have 
been few studies that have specifically determined risk factors 
associated with low-dose aspirin use, but many of the risk 
factors identified for nonaspirin NSAIDs have also been 
suggested as risk factors for low-dose aspirin-associated 
ulcers. In the US Preventative Services Task Force report on 
the use of aspirin for the primary prevention of cardiovascu-
lar disease, the risk was estimated to be two to three times 
higher in patients with a history of gastrointestinal ulcers and 
twice as high for men as for women.36 In a population-based 
case-control study of 1443 Danish patients with major upper 
gastrointestinal bleeding and 57,720 controls, the adjusted 
OR for gastrointestinal bleeding was 1.8 (95% CI: 1.5–2.1) 
for aspirin, 1.1 (95% CI: 0.6–2.1) for clopidogrel, 1.9 
(95% CI: 1.3–2.8) for dipyridamole, 1.8 (95% CI: 1.3–2.4) 
for vitamin K antagonists, 7.4 (95% CI: 3.5–15) for   aspirin and 
clopidogrel, 5.3 (95% CI: 2.9–9.5) for aspirin and   vitamin K 
antagonists, and 2.3 (95% CI: 1.7–3.5) for aspirin and dipyri-
damole.23,37 These results demonstrate that combined 
antithrombotic  therapy  with  low-dose  aspirin  is 
associated with a higher risk of gastrointestinal bleeding. 
Other risk factors that have been implicated in the devel-
opment of gastrointestinal ulcers during chronic aspirin 
use include advanced age ($60 years), presence of severe 
disease, concurrent use of COX-2 selective or nonselective 
NSAIDs, concurrent use of corticosteroids, symptoms of 
dyspepsia or GERD, and infection with H. pylori.38,39
Some observational studies also suggest that the risk of 
gastrointestinal bleeding is increased at higher aspirin doses. 
One large case control study in 2777 consecutive patients with 
endoscopy-proven major upper gastrointestinal bleeding and 
5532 controls showed clear dose dependency, with an adjusted 
RR, of 2.7 (95% CI: 2.0–3.6) for aspirin 100 mg daily, 6.1 
(95% CI: 4.3–8.7) for aspirin 300 mg daily, and 10.4 (6.1–17.8) 
for aspirin 1000 mg daily.10,40 However, in direct randomized 
comparisons, no significant associations were found between 
different low aspirin doses (75–325 mg daily) and risk of 
bleeding.20 Likewise, in indirect comparison in a meta-analysis 
conducted by the Antithrombotic Trialists’ Collaboration, there 
was no significant difference in risk at doses of 75–325 mg 
daily.10 The incidence of severe or life-threatening bleeding 
in relation to the aspirin dose (less than 100 mg, 100 mg, 
or more than 100 mg daily) was also evaluated in a nonran-
domized, post hoc subgroup analysis from the CHARISMA 
(Clopidogrel for High Atherothrombotic Risk and Ischemic 
Stabilization, Management, and Avoidance) trial.41 In this trial, 
nearly 16,000 patients with either established cardiovascular 
disease or at high risk were given aspirin in a daily dose left to 
the discretion of the investigators and were randomly assigned 
to concomitant clopidogrel 75 mg daily or placebo. At a 
median of 28 months, there were no significant differences in 
the incidence of severe or life-threatening bleeding between 
the different aspirin dose groups and no effect modification 
was found for clopidogrel.41 In the previously mentioned 
systematic review of 22 randomized trials of low-dose 
aspirin (75–325 mg/day) or clopidogrel, no difference was 
seen between 75–162.5 mg daily and 162.5–325 mg daily.33 
Therefore, the case for a dose-response relationship between 
aspirin dose and risk of gastrointestinal bleeding is not entirely 
clear, at least in the low-dose aspirin range up to 325 mg 
daily. Daily doses of 75 mg aspirin for a few consecutive days 
provides virtually complete inhibition of COX-1 in blood 
platelets, and doses above 75–150 mg do not confer addi-
tional benefits for the prevention of cardiovascular events.10 
Therefore, more than 150 mg aspirin should not be prescribed 
for cardiovascular risk reduction.
Risk reduction strategies
Several strategies have been proposed to minimize the 
risk of upper gastrointestinal bleeding in low-dose aspirin 
users. These include using the lowest effective aspirin dose 
(,100 mg daily), concomitant use of gastroprotective agents, Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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such as proton pump inhibitors, H2-receptor antagonists, or 
prostaglandin replacement with the prostaglandin E1 analog, 
misoprostol, use of alternative platelet inhibitors, such as 
clopidogrel and eradication of H. pylori.
Helicobacter pylori eradication
H. pylori and NSAIDs are the most important independent 
risk factors for peptic ulcers and ulcer bleeding, and peptic 
ulcers are rare in H. pylori-negative non-NSAID users.42 
There also appears to be synergism for the development of 
peptic ulcers and ulcer bleeding between H. pylori infection 
and NSAID use. The baseline risk for a new H. pylori ulcer 
in patients with latent H. pylori infection is approximately 
1% per year (1 per 100 patient years), independent of NSAID 
use. The baseline risk for a new H. pylori ulcer complica-
tion in patients with latent H. pylori infection is very small, 
ie, ,1 per 1000 patient years. However, in patients with 
a history of H. pylori-related ulcers, the baseline risk of 
endoscopic recurrence is 50%–100% within any one year, 
even without NSAID exposure. In patients with a history of 
H. pylori ulcer complications, the risk of a new ulcer com-
plication is 1%–3% per month, again even without NSAID 
exposure.43 A meta-analysis of observational studies showed 
that H. pylori infection and NSAID use increased the risk of 
ulcer bleeding 1.79-fold and 4.85-fold, respectively. However, 
the risk of ulcer bleeding increased to 6.13 when both fac-
tors were present.44 H. pylori eradication prevents or greatly 
reduces the risk of recurrence of H. pylori ulcers. However, 
in NSAID users, H. pylori eradication would be expected to 
be less effective. A meta-analysis of five randomized trials 
with 939 patients on the efficacy of H. pylori eradication in 
NSAID users showed that 7.4% patients developed a peptic 
ulcer in the eradicated group versus 13.3% in the control 
group (OR 0.43; 95% CI: 0.20–0.93). Subanalyses showed 
a significant risk reduction for NSAID-naïve patients (OR 
0.26, 95% CI: 0.14–0.49) but not in previous NSAID users 
(OR 0.95; 95% CI: 0.53–1.72).45 This is consistent with the 
view that H. pylori infection enhances NSAID gastrotoxicity 
or that NSAIDs exacerbate H. pylori ulcers or ulcerogenesis. 
The failure of H. pylori eradication in chronic NSAID users 
may reflect selection bias of H. pylori-positive NSAID survi-
vors, because patients who develop ulcers early after starting 
on NSAIDs would likely discontinue their NSAID treat-
ment.28 H. pylori infection is also associated with increased 
risk of gastrointestinal ulcers in low-dose aspirin users.46 
There have been no studies evaluating H. pylori eradication 
for the primary prevention of low-dose aspirin-associated 
ulcer bleeding. However, in low-dose aspirin users with 
ulcers or ulcer bleeding, eradication of H. pylori reduces the 
risk of recurrence.42,47 In one randomized controlled trial, 
400 H. pylori-positive patients with upper gastrointestinal 
  bleeding (250 with aspirin and 150 with other NSAIDs) were 
randomly assigned to omeprazole 20 mg daily for six months 
or one week of eradication therapy, while continuing on either 
aspirin 80 mg daily or naproxen 500 mg twice daily. Among 
those taking aspirin, the probability of recurrent bleeding 
during the six-month period was similar for patients who 
received eradication therapy and for patients who received 
omeprazole (1.9% and 0.9% respectively, absolute difference 
1.0%, 95% CI: for the difference, -1.9%–3.9%).47 In high-
risk patients with continued aspirin use over longer periods 
of time, H. pylori eradication alone may not be sufficient to 
prevent recurrent bleeding. In a randomized, controlled trial 
with 123 H. pylori-positive patients with low-dose aspirin-
associated ulcer complications, the patients were randomly 
assigned to lansoprazole 30 mg daily or placebo, in addition 
to aspirin 100 mg daily, for 12 months after ulcer healing 
and eradication of H. pylori infection. Recurrence of ulcer 
complications occurred in 14.8% in the placebo group and 
in 1.6% in the lansoprazole group (adjusted HR, 9.6, 95% 
CI: 1.2–76.1; P = 0.008).48
Gastroprotective agents
National and international guidelines for the prevention of 
NSAID-associated upper gastrointestinal complications con-
sistently recommend the use of proton pump inhibitors. In fact, 
there is a lack of prospective clinical trial data supporting this, as 
was demonstrated in a meta-analysis of randomized clinical trials 
on the prevention of NSAID-induced gastrointestinal ulcers.49 
Misoprostol was the only prophylactic agent documented to 
reduce NSAID ulcer complications such as perforation, bleed-
ing, or obstruction, but caused significant gastrointestinal side 
effects, such as abdominal pain and diarrhea, which limits its 
use in daily clinical practice. Both double-dose H2-receptor 
antagonists and proton pump inhibitors were effective at reduc-
ing the risk of endoscopic duodenal ulcers (RR, 0.44; 95% CI:   
0.26–0.74) and gastric ulcers (RR, 0.40; 95% CI: 0.32–0.51) 
and were better tolerated than misoprostol (Table 3).49
There are also limited data available on the efficacy of 
gastroprotective agents for the prevention of low-dose aspirin-
induced gastrointestinal complications. In a double-blind, 
placebo-controlled endoscopy study, 32 healthy volunteers 
took aspirin 300 mg daily for 28 days. Most subjects developed 
erosions of the gastric mucosa, which was significantly reduced 
by misoprostol 100 µg daily (OR, 0.18; 95% CI: 0.07–0.48) 
without causing identifiable adverse effects.50Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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Table 3 Efficacy of gastroprotective agents for the prevention of low-dose aspirin-associated gastrointestinal complications
Study Population Methods Results Conclusion
Misoprostol Donnelly  
et al50
Healthy volunteers  
(n = 32)
Double-blind,  
placebo-controlled 
endoscopy study
Reduced incidence  
of $1 gastric erosion  
when using  
misoprostol  
(17% aspirin- 
misoprostol versus  
52% aspirin-placebo,  
OR 0.18; 95%  
Ci 0.07–0.48)
Misoprostol can  
prevent low-dose  
aspirin-induced  
gastric mucosal  
injury
H2-receptor  
antagonists
Taha  
et al51
Patients with cardiovascular  
or cerebrovascular  
disease or diabetes  
using low-dose  
aspirin (n = 404)
Randomized, double-blind,  
placebo-controlled trial
Reduced incidence of  
endoscopic gastric ulcers  
(3.4% famotidine versus 15%  
placebo, OR 0.20; 95%  
Ci 0.09–0.47), duodenal  
ulcers (0.5% famotidine  
versus 8.5% placebo, OR 0.05;  
95% Ci 0.01–0.40), and erosive 
esophagitis (4.4% famotidine  
versus 19% placebo, OR 0.20;  
95% Ci 0.09–0.42)  
after 12 weeks
Famotidine is effective  
in the prevention of 
gastric and duodenal 
ulcers, and erosive 
esophagitis in patients 
taking low-dose aspirin
Lanas  
et al52
Patients with endoscopy  
confirmed upper 
gastrointestinal  
bleeding (n = 2777,  
5532 controls)
Case-control study Adjusted relative risk  
of 0.40 (95% Ci 0.19–0.73)  
for upper gastrointestinal 
bleeding in low-dose aspirin  
users with concomitant  
use of H2-receptor antagonists
H2-receptor antagonist 
use is associated 
with reduced upper 
gastrointestinal bleeding   
in patients taking aspirin
Lanas  
et al53
Patients taking low-dose  
aspirin for vascular  
prevention with endoscopy 
confirmed upper 
gastrointestinal  
bleeding (n = 323,  
matched controls)
Case-control study Adjusted relative  
risk of 0.50 (95%  
Ci 0.20–1.2) for  
upper gastrointestinal 
bleeding in low-dose 
aspirin users with 
concomitant use  
of H2-receptor  
antagonists
H2-receptor antagonist 
use is associated with a  
trend to reduced upper 
gastrointestinal bleeding 
in patients taking aspirin
Proton  
pump  
inhibitors
Yeomans  
et al56
elderly users of  
low-dose aspirin 
(n = 995)
Randomized  
placebo-controlled  
trial
Reduced incidence  
of endoscopic 
gastroduodenal  
ulcers after 26 weeks’ 
use of esomeprazole 
(1.6% esomeprazole 
versus 5.4% placebo, 
P = 0.0007)
esomeprazole reduces 
the risk of developing 
gastroduodenal ulcers 
in elderly patients 
taking low-dose aspirin
Lanas  
et al52
Patients with  
endoscopy  
confirmed upper 
gastrointestinal  
bleeding (n = 2777,  
5532 controls)
Case-control study Adjusted risk  
reduction of 0.32  
(95% Ci 0.22–0.51)  
for upper gastro  intestinal  
bleeding with  
concomitant use of  
proton pump inhibitors
Proton pump inhibitor 
use is associated 
with reduced upper 
gastrointestinal bleeding 
in patients taking aspirin
Lanas et al53 Patients taking low-dose 
aspirin for vascular  
prevention with endoscopy 
confirmed upper 
gastrointestinal bleeding 
(n = 323, matched controls)
Case-control study Adjusted relative  
risk of 0.20  
(95% Ci 0.10–0.90)  
for upper gastrointestinal  
bleeding in low-dose 
aspirin users with 
concomitant use of  
H2-receptor antagonists
Proton pump inhibitor 
use is associated 
with reduced upper  
gastrointestinal bleeding 
in patients taking aspirin
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Table 3 (Continued )
Study Population Methods Results Conclusion
Ng et al57 Patients with aspirin-related 
peptic ulcers/erosions 
(n = 160)
Randomized placebo-
controlled trial
Reduced recurrence  
of ulcers or erosions  
in patients taking proton 
pump inhibition  
compared with high dose 
H2-receptor antagonist 
after 48 weeks 
(0% pantoprazole 
versus 20% famotidine 
(P , 0.0001)
in patients with  
aspirin-related  
peptic ulcers/erosions 
famotidine is inferior 
to pantoprazole in 
preventing recurrence
Abbreviations: OR, odds ratio; CI, confidence interval.
H2-receptor antagonists including ranitidine, cimetidine, 
and famotidine, reduce the production of gastric acid through 
inhibition of the histamine H2-receptor. The efficacy of famo-
tidine in the primary prevention of gastroduodenal ulcers and 
erosive esophagitis in patients receiving low-dose aspirin 
was investigated in the FAMOUS (Famotidine for the Pre-
vention of Peptic Ulcers in Users of Low-dose Aspirin) trial,   
a randomized, double-blind, placebo-controlled trial from 
the UK.51 Patients taking aspirin 75–325 mg per day who 
did not have ulcers or erosive esophagitis on baseline 
endoscopy were randomly assigned to receive famotidine 
20 mg twice daily or placebo. Endoscopy at 12 weeks 
revealed gastric ulcers in seven of 204 (3.4%) patients on 
famotidine compared with 30 of 200 (15%) patients with 
placebo (OR, 0.20; 95% CI: 0.09–0.47), duodenal ulcers 
in one (0.5%) patient with famotidine compared with 17 
(8.5%) with placebo (OR, 0.05; 95% CI: 0.01–0.40) and 
erosive esophagitis in nine (4.4%) patients with famotidine 
compared with 38 (19%) patients with placebo (OR, 0.20; 
95% CI: 0.09–0.42). Four patients in the placebo group were 
admitted to hospital with upper gastrointestinal bleeding. 
Therefore, in patients taking low-dose aspirin for vascular 
protection, high-dose H2-receptor antagonist famotidine was 
found to be effective in the primary prevention of endoscopic 
ulcers and erosive oesophagitis.51 These data confirm results 
from previous observational studies. A large Spanish case-
control study in 2777 patients with endoscopically confirmed 
upper gastrointestinal bleeding and 5532 matched controls 
reported an adjusted RR, of 0.40 (95% CI: 0.19–0.73) for 
upper gastrointestinal bleeding in low-dose aspirin users 
with concomitant use of H2-receptor antagonists.52 Another 
case-control study from Spain in 323 patients with low-
dose aspirin (up to 300 mg daily for vascular protection) 
with endoscopically confirmed acute upper gastrointestinal 
bleeding and matched controls, also demonstrated a 50% 
risk reduction of acute upper gastrointestinal bleeding with 
concomitant H2-receptor antagonists (adjusted OR, 0.5; 95% 
CI: 0.2–1.2).53 There have been no randomized, placebo-
controlled trials demonstrating the efficacy of H2-receptor 
antagonists in the primary or secondary prevention of upper 
gastrointestinal ulcer complications.
Proton-pump inhibitors, including omeprazole, esome-
prazole, rabeprazole, pantoprazole, and lansoprazole, reduce 
the production of gastric acid by inhibiting the parietal cell 
pump. In healthy volunteers, omeprazole and lansoprazole 
significantly reduced the risk of endoscopic gastroduodenal 
lesions induced by aspirin 300 mg daily.54,55 The efficacy of 
esomeprazole for the primary prevention of gastroduodenal 
ulcers and erosive esophagitis and the treatment of dyspeptic 
symptoms in patients receiving continuous low-dose aspirin 
was investigated in a large randomized, placebo-controlled 
trial from Australia.57 Elderly patients aged 60 years and over, 
without gastroduodenal ulcers at baseline endoscopy who 
were receiving 75–325 mg aspirin daily were randomized 
to receive esomeprazole 20 mg daily or placebo. Endoscopy 
at 26 weeks revealed gastroduodenal ulcers in eight of 493 
(1.6%) patients with esomeprazole compared with 27 of 498 
(5.4%) patients in the placebo group (life-table estimates 
1.8% versus 6.2%, P = 0.0007). The cumulative proportion 
of patients with erosive esophagitis at 26 weeks was signifi-
cantly lower for esomeprazole than placebo (4.4% and 18.3%, 
respectively, P , 0.0001). Esomeprazole was also more likely 
to resolve symptoms of heartburn, acid regurgitation, and epi-
gastric pain (P , 0.05). Therefore, esomeprazole was found 
to be effective in the primary prevention of endoscopic ulcers 
and erosive esophagitis and in the treatment of dyspeptic 
symptoms in patients taking continuous low-dose aspirin for 
vascular protection.57 These data again confirm results from 
previous observational studies. In the two case-control studies 
from Spain that are mentioned above, concomitant use of pro-
ton pump inhibitors was associated with a significant reduc-
tion in the RR of upper gastrointestinal bleeding in low-dose 
aspirin users.52,53 Furthermore, and perhaps more importantly, 
both case-control studies reported greater risk reduction with Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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proton pump inhibitors than with H2-receptor antagonists.   
In the first case-control study, the adjusted risk reduction was 
0.32 (95% CI: 0.22–0.51) with proton pump inhibitors versus 
0.40 (95% CI: 0.19–0.73) with H2-receptor antagonists and, 
in the second case-control study, the adjusted risk reduction 
was 0.2 (95% CI: 0.1–0.9) with omeprazole versus 0.5 (95% 
CI: 0.2–1.2) with H2-receptor antagonists.52,53 The superiority 
of proton pump inhibitors over H2-receptor antagonists in 
the prevention of low-dose aspirin-related peptic ulcers was 
recently confirmed in a secondary prevention trial from Hong 
Kong.57 In this randomized, double-blind, controlled trial, 160 
patients with aspirin-related peptic ulcers or erosions, with 
or without a history of bleeding, were randomly assigned to 
either high-dose famotidine (40 mg, morning and evening) 
or pantoprazole (20 mg in the morning and placebo in the 
evening). All patients continued to receive aspirin 80 mg 
daily, and 130 patients (81.1%) completed the study. At 48 
weeks, 13 of 65 patients (20%) in the famotidine group had 
recurrent dyspeptic or bleeding ulcers or erosions (95% one-
sided CI for the risk difference 0.12–1.0) compared with 0 
of 65 patients (0%) in the pantoprazole group (P , 0.0001, 
95% one-sided CI for the risk difference 0.12–1.0). Gastro-
intestinal bleeding was significantly more common in the 
famotidine group (five of 65 patients; 7.7%) than in the pan-
toprazole group (0 of 65 patients; 0%), 95% one-sided CI for 
the risk difference 0.02–1.0; P = 0.03). Recurrent dyspepsia 
caused by ulcers or erosions was also significantly more com-
mon in the famotidine group (8 of 65 patients; 12.3%) than 
in the pantoprazole group (0 of 65 patients; 0%), with a 95% 
one-sided CI for the risk difference 0.06–1.0 (P = 0.003). No 
patients had ulcer perforation or obstructions. Therefore, 
in patients with low-dose aspirin-related peptic ulcers and 
continued aspirin use, pantoprazole was found to be superior 
to the high-dose H2-receptor antagonist, famotidine, in the 
secondary prevention of recurrent dyspeptic or bleeding 
ulcers and erosions.57
Whether or not aspirin therapy should be continued with 
concomitant proton pump inhibitors after endoscopic hemo-
static therapy in patients who develop ulcer bleeding whilst 
on low-dose aspirin for cardiovascular or cerebrovascular 
disease was investigated further in a parallel, double-blind, 
randomized, placebo-controlled noninferiority trial, again 
from Hong Kong.58 A total of 156 patients with peptic 
ulcer bleeding whilst on low-dose aspirin therapy were ran-
domly assigned to aspirin 80 mg daily or placebo for eight 
weeks immediately after endoscopic therapy. All patients 
received a 72-hour infusion of pantoprazole followed by 
oral pantoprazole, and all patients completed follow-up.   
At 30 days, endoscopically confirmed recurrent ulcer 
bleeding had occurred in 10.3% of the aspirin group and 
5.4% of the placebo group (95% CI for the difference, 
-3.6–13.4 percentage points). However, at eight weeks 
patients who received aspirin had lower all-cause mortality 
rates than patients who received placebo (1.3% versus 12.9%; 
95% CI for the difference, 3.7–19.5 percentage points) and 
lower mortality rates attributable to cardiovascular, cere-
brovascular, or gastrointestinal complications than patients 
in the placebo group (1.3% versus 10.3%; 95% CI for the 
difference, 1.7–16.3 percentage points). Therefore, among 
patients receiving low-dose aspirin therapy who had peptic 
ulcer bleeding, continued aspirin therapy may increase the 
risk of recurrent bleeding but potentially reduces mortality 
rates. However, the authors point out that the sample size was 
relatively small in this study, and that larger trials are needed 
to confirm the results.58
One potential drawback of combining low-dose aspirin 
with a proton pump inhibitor in patients with cardiovas-
cular disease could be a reduction in antiplatelet effect, 
which has recently been found in a case-control study of 
418 patients with coronary artery disease, 54 of whom 
received the combination of aspirin and a proton pump 
inhibitor. In this study, both platelet aggregation mea-
sured by whole blood aggregometry and platelet activa-
tion assessed by P-selectin were significantly higher in 
patients treated with a proton-pump inhibitor.59 However, 
this is the first study to find this effect. The data should 
be confirmed by other studies, as well as by studies of 
clinical endpoints.
Clopidogrel
Combination therapy with proton-pump inhibitors reduces 
the risk of aspirin-induced ulcer bleeding. However, compli-
ance issues may limit the usefulness of combination therapy, 
especially in patients already subject to polypharmacy. An 
alternative strategy would be to replace aspirin with a less 
ulcerogenic antiplatelet drug. Clopidogrel is an adenosine 
diphosphate receptor antagonist that inhibits platelet activa-
tion induced by adenosine diphosphate. Clopidogrel has been 
shown to prevent ischemic events and has been approved by 
the Food and Drug Administration for treatment of vascular 
diseases. In the international, randomized, blinded CAPRIE 
(Clopidogrel versus Aspirin in Patients at Risk of Ischaemic 
Events) trial, 19,185 patients with symptomatic atherosclero-
sis (recent ischemic stroke, recent myocardial infarction, or 
symptomatic peripheral arterial disease) were randomized to 
receive clopidogrel 75 mg daily or aspirin 325 mg daily for Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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1–3 years.60 At a mean follow-up of 1.91 years, compared 
with aspirin, clopidogrel reduced the combined risk of isch-
emic stroke, myocardial infarction, or vascular death by 8.7% 
(P = 0.043). The overall incidence of hemorrhagic events did 
not differ between the treatment groups (9.27% for clopidogrel 
versus 9.28% for aspirin; P = 0.98). Gastrointestinal hemor-
rhage was significantly less frequent with clopidogrel than 
with aspirin (1.99% for clopidogrel versus 2.66% for aspirin; 
P , 0.002). Overall, there were significantly fewer gastrointes-
tinal adverse events with clopidogrel than with aspirin (27.1% 
for clopidogrel versus 29.8% for aspirin; P , 0.001).60 Current 
guidelines recommend the use of clopidogrel for patients who 
are unable to take aspirin because of hypersensitivity or major 
gastrointestinal intolerance of aspirin.61 In two nearly identical 
randomized, controlled, double-blind trials from Hong Kong, 
clopidogrel was compared with aspirin plus esomeprazole for 
the prevention of recurrent bleeding from ulcers in high-risk 
patients.62,63 The first trial included 320 H. pylori-negative 
patients with ulcer bleeding whilst on low-dose aspirin. After 
the ulcers had healed, patients were randomly assigned to 
receive clopidogrel 75 mg daily plus placebo twice daily or 
aspirin 80 mg daily plus esomeprazole 20 mg twice daily for 
12 months. Recurrent ulcer bleeding occurred in 13 of 161 
patients receiving clopidogrel (cumulative 12-month inci-
dence 8.6%; 95% CI: 4.1%–13.1%) and in one of 159 patients 
receiving aspirin plus esomeprazole (cumulative 12-month 
incidence 0.7%; 95% CI: –2.0%) (absolute difference 7.9%; 
95% CI for the difference 3.4%–12.4%; P = 0.001).62 The 
second trial included 170 patients with ulcer bleeding whilst 
on low-dose aspirin. After the ulcers had healed and H. pylori, 
if present, was eradicated, patients were randomly assigned to 
treatment with clopidogrel 75 mg daily or esomeprazole 20 mg 
and aspirin 100 mg daily. After a median follow-up period of 
52 weeks, nine patients in the clopidogrel group (cumulative 
incidence 13.6%) versus 0 patients in the esomeprazole and 
aspirin group (cumulative incidence 0%) developed recurrent 
ulcer complications (absolute difference 13.6%; 95% CI for 
the difference 6.3–20.9%; P = 0.002).63 From both trials we 
can conclude that, among patients with a history of aspirin-
induced ulcer bleeding, the combination of esomeprazole and 
aspirin is superior to clopidogrel in preventing recurrent ulcer 
complications. The exact mechanism by which clopidogrel 
causes recurrent ulcer bleeding is not known. Animal stud-
ies have shown that platelet adenosine diphosphate-receptor 
antagonists impair the healing of gastric ulcers by suppressing 
the release of platelet-derived growth factors. Clopidogrel 
may therefore induce recurrent ulcers in previously damaged 
gastric mucosa.62
In patients with acute coronary syndromes, current 
  guidelines recommend the use of double antiplatelet therapy 
with both clopidogrel and aspirin. Double antiplatelet therapy 
is recommended for at least one month in unstable angina 
managed without intervention, for one year after non-ST-
  elevation myocardial infarction managed without intervention 
and for one year after ST-elevation myocardial infarction. 
In patients receiving placement of an intracoronary stent, 
double antiplatelet therapy may prevent stent thrombosis, an 
event associated with mortality rates of 20%–45%. Current 
guidelines recommend double antiplatelet therapy for at least 
one month after implantation of a bare metal coronary artery 
stent and for one year or more after a drug-eluting stent.61 
However, adding clopidogrel to aspirin has been shown to 
increase the risk of bleeding.64 In the previously mentioned 
population-based case-control study from Denmark, 1443 
cases of serious upper gastrointestinal bleeding were compared 
with 57,720 age and gender-matched controls. Adjusted OR 
for upper gastrointestinal bleeding was 1.8 (95% CI: 1.5–2.1) 
for low-dose aspirin, 1.1 (95% CI: 0.6–2.1) for clopidogrel, but 
7.4 (95% CI: 3.5–15) for the combination of clopidogrel and 
aspirin.37 Gastroduodenal bleeding in these patients would have 
the clinical consequence of at least discontinuing clopidogrel 
therapy which, in turn, would increase the risk of myocardial 
infarction or stent thrombosis. Current guidelines therefore 
recommend concomitant use of proton pump inhibitors in 
patients with a history of gastrointestinal bleeding, when aspi-
rin and clopidogrel are administered in combination or apart, 
to minimize the risk of recurrent gastrointestinal bleeding.61 
However, some but not all, observational studies have shown 
that the use of proton pump inhibitors in patients taking clopi-
dogrel is associated with an increased risk of reinfarction and 
death. In a population-based, nested case-control study among 
patients aged 66 years or older who commenced clopidogrel 
therapy following hospital discharge after treatment of acute 
myocardial infarction, cases were those readmitted with acute 
myocardial infarction within 90 days after discharge and 
event-free controls were matched on age, percutaneous coro-
nary intervention, and a validated risk score. Among 13,636 
patients prescribed clopidogrel, 734 cases and 2057 controls 
were identified. Current use of proton pump inhibitors was 
associated with an increased risk of reinfarction (adjusted OR, 
1.27, 95% CI: 1.0–1.57).65
Clopidogrel is a prodrug that is converted in the liver to an 
active metabolite, which then irreversibly inhibits the platelet 
adenosine diphosphate receptor, consequently inhibiting ade-
nosine diphosphate-induced platelet activation.   Clopidogrel 
bioactivation is mediated by hepatic cytochrome P450 Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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2C19, and the activity of cytochrome P450 2C19 strongly 
influences the antiplatelet effect of clopidogrel. Emerging 
evidence suggests that some proton pump inhibitors can 
inhibit cytochrome P450 2C19 and may thereby negatively 
alter clopidogrel’s pharmacokinetics.65 Several pharmaco-
dynamic ex vivo studies measuring platelet-phosphorylated, 
vasodilator-stimulated phosphoprotein, expressed as a plate-
let reactivity index or adenosine diphosphate-induced platelet 
aggregation as markers for platelet aggregation, reported that 
omeprazole significantly decreased clopidogrel’s inhibitory 
effect on platelets, but no difference was found for esomepra-
zole or lansoprazole, which do not inhibit cytochrome P450 
2C19.66,67 Furthermore, the population-based nested case-
control study mentioned earlier also found no association 
with pantoprazole for readmission with myocardial infarction 
(adjusted OR 1.02; 95% CI: 0.70–1.47).65 Therefore, some 
international experts now recommend avoiding proton pump 
inhibitors with the highest potential for interaction with 
clopidogrel (ie, omeprazole) in patients with clopidogrel. 
However, because the presence of proton-pump inhibitors 
and clopidogrel in plasma is short-lived, separation by 
12–20 hours should in theory prevent competitive inhibition 
of cytochrome P450 2C19 metabolism and minimize any 
potential clinical interaction. A proton-pump inhibitor may 
thus be given before breakfast and clopidogrel at bedtime, 
or a proton-pump inhibitor may be taken before dinner and 
clopidogrel at lunchtime.68
Conclusion
In summary, low-dose aspirin has proven itself for the 
  secondary prevention of cardiovascular events in high-risk 
patients, ie, individuals with previous occlusive cardio-
vascular or cerebrovascular disease. There is no evidence 
supporting the prescription of low-dose aspirin as primary 
prevention in individuals at low absolute risk, in individu-
als with a single risk factor like diabetes mellitus, or in 
individuals with suspected asymptomatic occlusive vas-
cular disease. Exact thresholds for treatment of individual 
patients at intermediate risk are not available, and whether 
the expected benefits in an individual outweigh the potential 
harm is to be judged by the treating physician. Furthermore, 
aspirin may have variable antiplatelet effects in individual 
patients, known as the phenomenon of “aspirin resistance”, 
which implies that some individuals may not benefit from 
long-term treatment with low-dose aspirin. The use of 
aspirin, in the low doses prescribed for cardiovascular risk 
reduction, is also associated with upper gastrointestinal side 
effects, ranging from acute mucosal damage to ulcers and 
ulcer complications. The damaging effects of aspirin, as 
well as nonaspirin NSAIDs, on the gastrointestinal mucosa 
are mainly systemic, induced by inhibition of COX-1 
and subsequent suppression of prostaglandin-mediated 
gastrointestinal defenses and blood platelet aggregation. 
The RR of gastrointestinal bleeding in aspirin users is 
in the range 1.3–3.2.28 Risk factors include a history of 
ulcers, age $60 years, combined antithrombotic therapy, 
concurrent NSAIDs or corticosteroids, and infection with 
H. pylori. Appropriate strategies to minimize the risk of 
upper gastrointestinal bleeding in low-dose aspirin users 
include H. pylori eradication in patients with previous ulcers 
and use of gastroprotective agents, ie, misoprostol, high-
dose H2-receptor antagonists or proton-pump inhibitors. 
Clopidogrel may by unknown mechanisms induce recur-
rent ulcers in previously damaged gastric mucosa. Among 
patients with a history of aspirin-induced ulcer bleeding, 
the combination of esomeprazole and aspirin is superior 
to clopidogrel monotherapy in preventing recurrent ulcer 
complications. Adding clopidogrel to aspirin, as is recom-
mended in protocols for the management of patients at high 
risk for occlusive coronary events, has been associated with 
an increased risk of bleeding. In these patients, the copre-
scription of a proton-pump inhibitor should be considered 
to reduce the gastrointestinal risk. However, because of 
a potential cytochrome P450 2C19-mediated interaction 
between proton-pump inhibitors and clopidogrel, the agent 
with the highest potential for interaction, ie, omeprazole, 
should either be avoided or dosages should be separated 
by at least 12 hours to preserve clopidogrel’s inhibitory 
effect on platelets.
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